Latin America Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Country (Brazil, Mexico, Argentina, Chile, Colombia, Rest of LATAM) Forecasts, 2026-2034

Market Overview

The worldwide neurodegenerative disease market size was valued at USD 3.10 billion in 2025 and is projected to grow from USD 3.31 billion in 2026 to reach USD 5.58 billion by 2034, growing at a CAGR of 6.74% during the forecast period (2026-2034).

In most cases, neurodegenerative disorders are characterised by gradual nerve cell degeneration that can occur in a variety of locations across the body. Loss of memory and cognitive control are potential outcomes of a number of conditions, including Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and amyotrophic lateral sclerosis (ALS).

Although there are very few diseases that can be cured, the pharmaceutical industry has developed a variety of treatments throughout the years that aim to alleviate the symptoms of neurodegenerative ailments.

Neurodegenerative disorders are a varied group of ailments defined by the gradual degradation of the function and structure of the central nervous system or peripheral nervous system. Neurodegenerative disorders, including Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Huntington's disease, have been rising globally. Thus, the growing burden of this condition is the key driver driving the market expansion, adding to it the expanding elderly population. According to NIH, nearly 1.2 million people in the United States will have Parkinson's disease by 2030. In the United States, it is the second most frequent neurodegenerative disorder.

Furthermore, according to Alzheimer's Disease International, more than 50 million adults with dementia globally in 2020. This number is anticipated to be more than double every two decades, reaching 82 million in 2030 and 152 million in 2050. Additionally, much of the increase will be in emerging countries. About 60% of persons with dementia reside in poor and middle-income nations, but by 2050, this will climb to 71%. The fastest rise in the senior population has happened in China, India, and South Asian and western Pacific countries. Thus, the growing burden of dementia is likely to enhance the market growth in the approaching years.

Latin America Neurodegenerative Disease Market Segmental Analysis

By Disease Indication

The Latin America neurodegenerative disease market is segmented by disease indication into multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others. Multiple sclerosis contributes to demand for long-term disease management, regular monitoring, and therapies aimed at controlling disease activity. Parkinson's disease is also an important indication as the region's aging population and increasing healthcare awareness contribute to greater recognition of progressive movement disorders. Alzheimer's disease is gaining attention with the growing prevalence of age-associated cognitive decline and increasing awareness among patients, caregivers, and healthcare professionals. Improvements in neurological diagnostics, specialist consultations, and access to treatment are gradually supporting earlier identification and management of these conditions across Latin American countries.

The others category includes a broad range of neurodegenerative and neurological disorders that require specialized diagnosis and therapeutic management. Increasing awareness of neurological health, improvements in diagnostic capabilities, and expansion of specialized healthcare services are creating opportunities for this segment. Rising healthcare expenditure and investments in hospital infrastructure are also supporting greater access to neurological care in major Latin American markets. However, variations in healthcare infrastructure, treatment affordability, reimbursement coverage, availability of specialists, and access to advanced medicines continue to influence treatment adoption across countries. Continued development of targeted therapies and improvements in neurological care are expected to strengthen the overall disease indication segment.

Request Customizationto receive a tailored report.

By Drug Type

The Latin America neurodegenerative disease market is classified by drug type into immunomodulator, vesicular monoamine transporter 2 (VMAT2), and others. Immunomodulators are relevant for neurological conditions in which immune-system activity contributes to disease mechanisms, creating demand for treatments capable of influencing abnormal immune responses. VMAT2-targeted therapies represent a specialized drug category associated with neurotransmitter regulation and the management of certain movement-related neurological symptoms. Growing awareness of advanced treatment options and improvements in neurological diagnosis are gradually increasing opportunities for these drug types. Adoption is expected to be comparatively stronger in countries with established specialist healthcare networks and greater availability of innovative medicines.

The others segment comprises therapeutic drugs that operate through mechanisms outside immunomodulation and VMAT2 targeting. These medicines may be used to manage neurological symptoms, support disease control, or address specific biological pathways associated with individual conditions. Ongoing pharmaceutical research is expanding the potential treatment landscape and may introduce therapies with improved efficacy, tolerability, or treatment convenience. In Latin America, market development is influenced by regulatory approvals, medicine pricing, reimbursement policies, physician awareness, treatment availability, and healthcare infrastructure. Improvements in pharmaceutical distribution and specialist services could gradually increase access to a broader range of neurological therapies.

By Routes of Administration

The Latin America neurodegenerative disease market is segmented by routes of administration into oral, intravenous (IV) delivery, and others. Oral administration remains an important treatment route because tablets and capsules are convenient for patients requiring long-term therapy and can generally be used in outpatient settings. The convenience of oral medicines can support treatment adherence and reduce dependence on frequent visits to healthcare facilities. Intravenous (IV) delivery is used for therapies requiring direct administration into the bloodstream, controlled dosing, or professional supervision. Expansion of hospitals, specialty clinics, and infusion facilities in major healthcare markets is supporting greater availability of IV-based treatment options.

The others category includes alternative administration methods that may be selected based on drug formulation, therapeutic requirements, disease severity, and patient needs. Advances in drug-delivery technologies are creating opportunities for formulations that can improve absorption, maintain consistent therapeutic exposure, or provide greater convenience. The selection of an administration route depends on clinical considerations as well as the availability of appropriate healthcare facilities. Across Latin America, adoption of different delivery methods will be influenced by treatment costs, healthcare infrastructure, reimbursement systems, regulatory requirements, specialist availability, and access to innovative neurological therapies.

Speak to an Analystto discuss market opportunities.

Latin America Neurodegenerative Disease Market Regional Analysis

In terms of geography, Brazil held the greatest portion of the Latin America neurodegenerative diseases market in 2022, followed by Argentina with a significant market share. The regional markets in these regions will be supported by factors such as the high awareness among the senior population, increasing research funding and grants, favourable government regulations, and a high prevalence of neurological illness. The World Health Organization (WHO) has reported that the number of fatalities caused by Parkinson's disease in Brazil has reached 3,980, which accounts for 0.38% of all deaths, and that a total of 240 incident cases of PD have been found. In the meanwhile, the gross incidence was recorded as 31.24 cases per 100,000 people, while the prevalence was 395 cases per 100,000 people in Mexico's population over the age of 40. According to the most recent available information, the ratio of males to females in the population of Mexico is 1.32.

The regional markets in Argentina, Mexico, Peru, and Columbia are anticipated to be driven by other reasons such as the rapidly rising population of elderly people, promising clinical treatments, and attractive reimbursement policies.

List of Key and Emerging Players in Latin America Neurodegenerative Disease Market